CEP-32496

US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
Pharmabiz
Sat, 05/19/12 - 12:26 pm
Ambit Biosciences
Teva Pharmaceuticals
CEP-32496
cancer
melanoma
lung cancer
thyroid cancer
colon cancer
ovarian cancer